美托洛尔联合曲美他嗪治疗冠心病心力衰竭的效果  

Efficacy of Metoprolol Combined with Trimetazidine in Treatment of Coronary Heart Failure

作　　者：林辉 LIN Hui(Fuqing Second Hospital,Fuzhou 350315,China)

机构地区：[1]福州市福清市第二医院,福建福州350315

出　　处：《中国医药指南》2023年第32期100-102,共3页Guide of China Medicine

摘　　要：目的分析美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果。方法分析2021年3月至2022年3月期间福清市第二医院的78例冠心病心力衰竭患者的临床数据。采取随机数表法分为治疗A组和B组,每组39例。治疗B组行美托洛尔治疗,治疗A组在上述基础上采取曲美他嗪治疗。评价两组治疗有效率、脑钠肽(BNP)水平、心功能指标、不良反应率及生活质量。结果治疗有效率中,治疗A组高于治疗B组(P<0.05)。BNP水平中,治疗前两组比较无差异(P>0.05),治疗后治疗A组低于治疗B组(P<0.05)。心功能指标中,治疗前两组比较无差异(P>0.05),治疗后治疗A组各项指标均优于治疗B组(均P<0.05)。不良反应发生率中,治疗A组低于治疗B组(P<0.05)。生活质量评分中,治疗前两组比较无差异(P>0.05),治疗后治疗A组各项评分均高于治疗B组(均P<0.05)。结论美托洛尔联合曲美他嗪治疗冠心病心力衰竭效果确切,相比单用美托洛尔,可提升治疗有效率,改善患者的BNP水平,提升心功能,治疗安全性良好,患者生活质量提升。Objective To analyze the clinical efficacy of metoprolol combined with trimetazidine in treating heart failure(HF)patients with coronary heart disease(CHD).Methods Seventy-eight cases of coronary heart failure patients admitted to Fuqing Second Hospital between March 2021 and March 2022 were extracted as the subjects of this study.Random number table method was adopted to divide them into treatment group B and treatment group A,with 39 cases in each group,in which treatment group B was treated with metoprolol and treatment group A was treated with trimetazidine on the basis of the above.The treatment efficiency,brain natriuretic peptide(BNP)level,cardiac function indexes,incidence of adverse reactions and quality of life scores were used to evaluate the treatment effects of the two groups.Results In the treatment efficiency,group A was higher than group B(P<0.05).There was no statistical difference in the BNP level between the two groups before treatment,and after treatment,group A was lower than group B(P<0.05).In the cardiac function indexes,there was no difference between the two groups before treatment(P>0.05),and all indexes in group A were better than those in group B after treatment(all P<0.05).For the incidence of adverse reactions,group A was lower than group B(P<0.05).There was no statistical in the quality of life score difference between the two groups before treatment,all scores in group A were higher than those in group B after treatment(all P<0.05).Conclusions Metoprolol combined with trimetazidine is effective in the treatment of CHD patients with heart failure,which can improve the effective rate of treatment,improve the BNP level of patients,improve their cardiac function,and have high treatment safety,thus promoting the quality of life of patients.This treatment method is worth promoting in clinical practice.

关 键 词：美托洛尔 曲美他嗪 冠心病 心力衰竭 

分 类 号：R541.4[医药卫生—心血管疾病]